Potential role of tigecycline in the treatment of community-acquired bacterial pneumonia

Infection and Drug Resistance

Volumn 4, Issue 1, 2011, Pages 77-86

  Townsend, Mary L ^a,b   Pound, Melanie W ^a,c   Drew, Richard H ^a,d  

^a CAMPBELL UNIVERSITY   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c NEW HANOVER REGIONAL MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Community acquired pneumonia; Glycylcycline; Tigecycline

Indexed keywords

CILASTATIN PLUS IMIPENEM; LEVOFLOXACIN; ORAL CONTRACEPTIVE AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; WARFARIN;

ABDOMINAL INFECTION; ACUTE PANCREATITIS; ANAPHYLAXIS; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; BACTERIAL VIRULENCE; CAUSE OF DEATH; CHLAMYDOPHILA PNEUMONIAE; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HAEMOPHILUS INFLUENZAE; HEADACHE; HEALTH CARE UTILIZATION; HUMAN; HYPERBILIRUBINEMIA; IN VITRO STUDY; INTRAHEPATIC CHOLESTASIS; JAUNDICE; KLEBSIELLA PNEUMONIAE; LEGIONELLA PNEUMOPHILA; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MORAXELLA CATARRHALIS; MYCOPLASMA PNEUMONIAE; NAUSEA; NONHUMAN; PHLEBITIS; REVIEW; SIDE EFFECT; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; VOMITING;

EID: 79952665770     PISSN: 11786973     EISSN: None     Source Type: Journal    
DOI: 10.2147/IDR.S6030     Document Type: Review

References (95)

1. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B. Deaths: final data for 2006. Natl Vital Stat Rep. 2009;57(14):1-134.
2. Colice GL, Morley MA, Asche C, Birnbaum HG. Treatment costs of community-acquired pneumonia in an employed population. Chest. 2004;125(6):2140-2145.
3. Niederman MS, Mandell LA, Anzueto A, et al; American Thoracic Society. Guidelines for the management of adults with communityacquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163(7): 1730-1754.
4. Mandell LA, Wunderink RG, Anzueto A, et al; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44 Suppl 2:S27-S72.
5. BTS Pneumonia Guidelines Committee. British Thoracic Society guidelines for the management of community-acquired pneumonia in adults-2004 Update. Available from: http://www.britthoracic.org.uk/Portals/0/Clinical%20Information/Pneumonia/Guidelines/MACAPrevisedApr04.pdf. Accessed December 8, 2010.
6. Woodhead M, Blasi F, Ewig S, et al; European Respiratory Society; European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2005;26(6):1138-1180.
7. Felmingham D. Comparative antimicrobial susceptibility of respiratory tract pathogens. Chemotherapy. 2004;50 Suppl 1:3-10.
8. Johnson DM, Stilwell MG, Fritsche TR, Jones RN. Emergence of multidrug- resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003). Diagn Microbiol Infect Dis. 2006;56(1):69-74.
9. Gordon KA, Biedenbach DJ, Jones RN. Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community- acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis. 2003;46(4):285-289.
10. Townsend ML, Pound MW, Drew RH. Tigecycline: a new glycylcycline antimicrobial. Int J Clin Pract. 2006;60(12):1662-1672.
11. Wyeth Pharmaceuticals. Tygacil (Package Insert). Philadelphia (PA): Wyeth Pharmaceuticals; 2010.
12. Breedt J, Teras J, Gardovskis J, et al; Tigecycline 305 cSSSI Study Group. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother. 2005;49(11):4658-4666.
13. Sacchidanand S, Penn RL, Embil JM, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis. 2005;9(5):251-261.
14. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E; Tigecycline 301 Study Group; Tigecycline 306 Study Group. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis. 2005; 41 Suppl 5:S354-S367.
15. Bergallo C, Jasovich A, Teglia O, et al; 308 Study Group. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis. 2009;63(1):52-61.
16. Tanaseanu C, Milutinovic S, Calistru PI, et al; 313 Study Group. Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. BMC Pulm Med. 2009;9:44.
17. Tanaseanu C, Bergallo C, Teglia O, et al, 308 Study Group; 313 Study Group. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis. 2008;61(3):329-338.
18. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 2001;65(2):232-260.
19. Chopra I, Hawkey PM, Hinton M. Tetracyclines, molecular and clinical aspects. J Antimicrob Chemother. 1992;29(3):245-277.
20. Speer BS, Shoemaker NB, Salyers AA. Bacterial resistance to tetracycline: mechanisms, transfer, and clinical significance. Clin Microbiol Rev. 1992;5(4):387-399.
21. Bergeron J, Ammirati M, Danley D, et al. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother. 1996;40(9):2226-2228.
22. Rasmussen BA, Gluzman Y, Tally FP. Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines. Antimicrob Agents Chemother. 1994;38(7):1658-1660.
23. Tally FT, Ellestad GA, Testa RT. Glycylcyclines: a new generation of tetracyclines. J Antimicrob Chemother. 1995;35(4):449-452.
24. Projan SJ. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy. 2000;20(9 Pt 2):219S-223S.
25. Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004;64(1):63-88.
26. Dean CR, Visalli MA, Projan SJ, Sum PE, Bradford PA. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother. 2003;47(3):972-978.
27. Hornsey M, Ellington MJ, Doumith M, Scott G, Livermore DM, Woodford N. Emergence of AcrAB-mediated tigecycline resistance in a clinical isolate of Enterobacter cloacae during ciprofloxacin treatment. Int J Antimicrob Agents. 2010;35(5):478-481.
28. Hornsey M, Ellington MJ, Doumith M, Hudson S, Livermore DM, Woodford N. Tigecycline resistance in Serratia marcescens associated with up-regulation of the SdeXY-HasF efflux system also active against ciprofloxacin and cefpirome. J Antimicrob Chemother. 2010;65(3): 479-482.
29. Wieczorek P, Sacha P, Hauschild T, Zórawski M, Krawczyk M, Tryniszewska E. Multidrug resistant Acinetobacter baumannii-the role of AdeABC (RND family) efflux pump in resistance to antibiotics. Folia Histochem Cytobiol. 2008;46(3):257-267.
30. Rajendran R, Quinn RF, Murray C, McCulloch E, Williams C, Ramage G. Efflux pumps may play a role in tigecycline resistance in Burkholderia species. Int J Antimicrob Agents. 2010;36(2):151-154.
31. Hentschke M, Wolters M, Sobottka I, Rohde H, Aepfelbacher M. ramR mutations in clinical isolates of Klebsiella pneumoniae with reduced susceptibility to tigecycline. Antimicrob Agents Chemother. 2010;54(6): 2720-2723.
32. Clinical and Laboratory Standards Institute (CLSI) [formerly National Committee for Clinical Laboratory Standards (NCCLS)]. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. 8th ed. Wayne (PA): CLSI; 2009.
33. Clinical and Laboratory Standards Institute (CLSI) [formerly National Committee for Clinical Laboratory Standards (NCCLS)]. Performance Standards for Antimicrobial Susceptibility Testing-19th Informational Supplement. Wayne (PA): CLSI; 2009.
34. Clinical and Laboratory Standards Institute (CLSI) [formerly National Committee for Clinical Laboratory Standards (NCCLS)]. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria. 7th ed. Wayne (PA): CLSI; 2007.
35. Sader HS, Jones RN, Stilwell MG, Dowzicky MJ, Fritsche TR. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis. 2005;52(3):181-186.
36. Darabi A, Hocquet D, Dowzicky MJ. Antimicrobial activity against Streptococcus pneumoniae and Haemophilus influenzae collected globally between 2004 and 2008 as part of the Tigecycline Evaluation and Surveillance Trial. Diagn Microbiol Infect Dis. 2010;67(1):78-86.
37. Garrison MW, Nuemiller JJ. In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. Int J Antimicrob Agents. 2007;29(2):191-196.
38. Yamamoto T, Nishiyama A, Takano T, et al. Community-acquired methicillin-resistant Staphylococcus aureus: community transmission, pathogenesis, and drug resistance. J Infect Chemother. 2010;16(4): 225-254.
39. Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-2004 influenza season. Emerg Infect Dis. 2006;12(6):894-899.
40. Napolitano LM, Brunsvold ME, Reddy RC, Hyzy RC. Communityacquired methicillin-resistant Staphylococcus aureus pneumonia and ARDS: 1-year follow-up. Chest. 2009;136(5):1407-1412.
41. Mendes RE, Sader HS, Deshpande L, Jones RN. Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers. Diagn Microbiol Infect Dis. 2008;60(4):433-436.
42. Smith K, Gould KA, Ramage G, Gemmell CG, Hinds J, Lang S. Influence of tigecycline on expression of virulence factors in biofilm- associated cells of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2010;54(1):380-387.
43. Zhanel GG, Palatnick L, Nichol KA, Low DE, Hoban DJ; CROSS Study Group. Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother. 2003;47(6):1875-1881.
44. Ko KS, Song JH, Lee MY, et al. Antimicrobial activity of tigecycline against recent isolates of respiratory pathogens from Asian countries. Diagn Microbiol Infect Dis. 2006;55(4):337-341.
45. Waites KB, Duffy LB, Dowzicky MJ. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob Agents Chemother. 2006;50(10): 3479-3484.
46. Dowzicky MJ, Park CH. Update on antimicrobial susceptibility rates among Gram-negative and Gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007. Clin Ther. 2008;30(11):2040-2050.
47. Halstead DC, Abid J, Dowzicky MJ. Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial. J Infect. 2007;55(1):49-57.
48. Bradford PA, Weaver-Sands DT, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis. 2005; 41 Suppl 5:S315-S332.
49. El-Solh AA, Pietrantoni C, Bhat A, et al. Microbiology of severe aspiration pneumonia in institutionalized elderly. Am J Respir Crit Care Med. 2003;167(12):1650-1654.
50. Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother. 2001;45(9):2604-2608.
51. Roblin PM, Hammerschlag MR. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis. Int J Antimicrob Agents. 2000;16(1):61-63.
52. Wyeth Pharmaceuticals. Response Letter for Tigecycline Inquiry Regarding Legionella pneumophilia in vitro Data (Data on File). Philadelphia (PA): Wyeth Pharmaceuticals; 2010.
53. Edelstein PH, Weiss WJ, Edelstein MA. Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother. 2003;47(2):533-540.
54. Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother. 2005;49(1):220-229.
55. Rubino CM, Forrest A, Bhavnani SM, et al. Tigecycline population pharmacokinetics in patients with community-or hospitalacquired pneumonia. Antimicrob Agents Chemother. 2010;54(12): 5180-5186.
56. Darling IM, Cirincione BB, Owen JS. Noncompartmental pharmacokinetics of tigecycline in Phase 3 studies of patients with complicated skin and skin-structure and intra-abdominal infections. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy [meeting abstract]; December 16-19, 2005; Washington, DC.
57. Macgowan AP. Tigecycline pharmacokinetic/pharmacodynamic update. J Antimicrob Chemother. 2008;62 Suppl 1:i11-i16.
58. Tombs NL. Tissue distribution of GAR-936, a broad spectrum antibiotic in male rats. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy [meeting abstract]; September 14-17, 1999; Chicago, IL.
59. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Tigeycline (TGC) concentration (Cp) in lung tissue, cerebrospinal fluid (CSF), and bile of human subjects. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy [meeting abstract]; December 16-19, 2005; Washington, DC.
60. Conte JE Jr, Golden JA, Kelly MG, Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents. 2005;25(6):523-529.
61. Gotfried MH, Rodvold KA, Cwik M, Troy SM, Dukart G, Ellis-Grosse EJ. An open-label clinical evaluation of tigecycline concentrations in selected tissues and fluids. Clin Pharmacol Ther. 2005;77 Suppl 2:98.
62. Sun HK, Ong CT, Umer A, et al. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother. 2005;49(4):1629-1632.
63. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother. 2006;58(6): 1221-1229.
64. Scheetz MH, Reddy P, Nicolau DP, et al. Peritoneal fluid penetration of tigecycline. Ann Pharmacother. 2006;40(11):2064-2067.
65. Burkhardt O, Rauch K, Kaever V, Hadem J, Kielstein JT, Welte T. Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int J Antimicrob Agents. 2009;34(1): 101-102.
66. Baldwin DR, Honeybourne D, Wise R. Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrob Agents Chemother. 1992;36(6):1176-1180.
67. Hoffmann M, DeMaio W, Jordan RA, et al. Metabolic disposition (14C) tigecycline in human volunteers following intravenous infusion. American Association of Pharmaceutical Scientists (AAPS) Annual Meeting [meeting abstract]; November 7-11, 2004; Baltimore, MD.
68. Rello J. Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline. J Chemother. 2005;17 Suppl 1:12-22.
69. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. Pharmacokinetic/ pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis. 2005; 52(3):165-171.
70. Muralidharan G, Fruncillo RJ, Micalizzi M, Raible DG, Troy SM. Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects. Antimicrob Agents Chemother. 2005;49(4):1656-1659.
71. Troy SM, Muralidharan G, Micalizzi M, Mojavarian P, Salacinski L, Raible D. The effects of renal disease on the pharmacokinetics of tigecycline (GAR-936). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy [meeting abstract]; September 14-17, 2003; Chicago, IL.
72. Saunders S, Baird-Bellaire SJ, Patat AA, et al. Pharmacokinetics of tigecycline (TGC) in patients with hepatic impairment. European Association for Clinical Pharmacology and Therapeutics [meeting abstract]; June 24-29, 2005; Poznan, Poland.
73. Korth-Bradley JM, Baird-Bellaire SJ, Patat AA, et al. Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis. J Clin Pharmacol. 2011;51(1):93-101.
74. Meagher AK, Passarell JA, Cirincione BB, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother. 2007;51(6): 1939-1945.
75. Passarell JA, Meagher AK, Liolios K, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 2008;52(1):204-210.
76. Rubino CM, Bhavnani S, Forrest A, et al. Pharmacokinetic- pharmacodynamic analysis for efficacy of tigecycline in patients with hospital-or community-acquired pneumonia. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy [meeting abstract]; September 17-20, 2007; Chicago, IL.
77. Falagas ME, Karageorgopoulos DE, Dimopoulos G. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline. Curr Drug Metab. 2009;10(1):13-21.
78. Van Ogtrop ML, Andes D, Stamstad TJ, et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various Gram-positive and Gram-negative bacteria. Antimicrob Agents Chemother. 2000;44(4):943-949.
79. Hoffmann M, DeMaio W, Jordan RA, et al. Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. Drug Metab Dispos. 2007;35(9):1543-1553.
80. Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother. 2006;58(2):256-265.
81. Cunha BA. Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis. J Clin Microbiol. 2009;47(5):1613.
82. Cunha BA. Once-daily tigecycline therapy of multidrug-resistant and non-multidrug-resistant Gram-negative bacteremias. J Chemother. 2007;19(2):232-233.
83. Freire AT, Melnyk V, Kim MJ, et al. 311 Study Group. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis. 2010;68(2):140-151.
84. Peres E, Khaled Y, Krijanovski OI, et al. Mycobacterium chelonae necrotizing pneumonia after allogeneic hematopoietic stem cell transplant: report of clinical response to treatment with tigecycline. Transpl Infect Dis. 2009;11(1):57-63.
85. Blanquer D, de Otero J, Padilla E, et al. Tigecycline for treatment of nosocomial- acquired pneumonia possibly caused by multi-drug resistant strains of Stenotrophomonas maltophilia. J Chemother. 2008;20(6): 761-763.
86. Daly MW, Riddle DJ, Ledeboer NA, Dunne WM, Ritchie DJ. Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae. Pharmacotherapy. 2007;27(7):1052-1057.
87. Vasilev K, Reshedko G, Orasan R, et al. 309 Study Group. A Phase 3, openlabel, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother. 2008;62 Suppl 1:i29-i40.
88. Hung WY, Kogelman L, Volpe G, Iafrati M, Davidson L. Tigecyclineinduced acute pancreatitis: case report and literature review. Int J Antimicrob Agents. 2009;34(5):486-489.
89. Lipshitz J, Kruh J, Cheung P, Cassagnol M. Tigecycline-induced pancreatitis. J Clin Gastroenterol. 2009;43(1):93.
90. Gilson M, Moachon L, Jeanne L, et al. Acute pancreatitis related to tigecycline: case report and review of the literature. Scand J Infect Dis. 2008;40(8):681-683.
91. FDA Drug Safety Communication. Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm#ds. Accessed November 11, 2010.
92. Curcio D. Tigecycline for severe infections: the gap between the warning and the necessity. J Antimicrob Chemother. 2010. Epub ahead of print.
93. Zimmerman JJ, Harper D, Matschke K, Speth J, Raible DJ, Fruncillo RJ. Tigecycline and digoxin co-administered to healthy men. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy [meeting abstract]; October 30-November 2, 2004; Washington, DC.
94. Raible D, Zimmerman JJ, Harper D, Speth J. Pharmacokinetics and pharmacodynamics of tigecycline and warfain coadministered to healthy subjects. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy [meeting abstract]; December 16-19, 2005; Washington, DC.
95. Garrison MW, Mutters R, Dowzicky MJ. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007. Diagn Microbiol Infect Dis. 2009;65(3): 288-299.